Scale -


  • Revenue is 4078 Rs Cr; 5 Year CAGR is 20 %
  • Ebitda is 1734 Rs Cr; 5 Year CAGR is 48 %; Annual Decline is -32 %
  • PBT is 186 Rs Cr; 5 Year CAGR is 65 %; Annual Decline is -35 %
  • PAT is 1372 Rs Cr; 5 Year CAGR is 69 %; Annual Decline is -27 %
  • Quarterly Ebitda is 186 Rs Cr; in Bottom Quartile

Profitability -


  • PBDIT Margin is 42.52 %; in Top Quartile; 5 Year CAGR is 23 %; Annual Decline is -26 %
  • PAT Margin is 33.63 %; in Top Quartile; 5 Year CAGR is 40 %; Annual Decline is -21 %

Return -


  • ROCE is 16.26 %; 5 Year CAGR is 34 %; Annual Decline is -46 %
  • ROA is 12.8 %; 5 Year CAGR is 40 %; Annual Decline is -41 %
  • ROE is 15.38 %; 5 Year CAGR is 40 %; Annual Decline is -38 %
  • Asset Turnover is 41 %; Annual Decline is -28 %; Continuous Decline over 3 years; in Bottom Quartile

Efficiency -


  • Operating cash flow is 1768 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 148 %
  • Current Ratio is 3.01; in Top Quartile; Annual Decline is -46 %
  • Quick Ratio is 2.47; in Top Quartile; Annual Decline is -48 %
  • Inventory Turnover Ratio is 4.87; 5 Year CAGR is 63 %

Solvancy -


  • Contingent Liabilities is 0 Rs Cr; Annual Decline is -100 %; Continuous Decline over 3 years; in Bottom Quartile
  • Debt/Equity is 0.08; Annual Growth is 100 %
  • Total Debt is 706 Rs Cr; Annual Growth is 159 %

Quality -


  • Operating cashflow/ebitda is 102 %; Annual Growth is 53 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 68 %
  • Operating cashflow/PAT is 129 %; Annual Growth is 43 %; Continuous Growth over 3 years; 5 Year CAGR is 47 %
  • Current Tax/PAT is 9 %; Annual Decline is -63 %; in Bottom Quartile; 5 Year CAGR is -25 %
  • Change in Inventories/Total Expenses is -4 %; Annual Decline is -634 %; Continuous Decline over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile
  • Other Expenses/Total Expenses is 44 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Natco Pharma promoter group acquires shares via rights issue allotment
Natco Pharma ?? Rights Issue ?????! ?.? ???? ???????? ????, ????????????????? ?????????? ?????
Natco Pharma Allots 1.7 Crore Shares Via Rights Issue at ?750
NATCO Pharma Launches Generic Carboplatin Injection in US
NATCO Pharma subsidiary launches Carboplatin in US market to address shortages
Natco Pharma promoter pledges 8.5 lakh shares to Bajaj Financial
Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key Details
NATCO Pharma Raises Investment in eGenesis to $16.70 Mn